Iambic Presents Updated Iam1363 Clinical Data At Esmo 2026, Showing Durable Responses With A Favorable Tolerability Profile In Heavily Pretreated Participants With Her2-Driven Cancers
Leggi l'articolo completo
Ottieni accesso illimitato agli articoli di Reuters e a tutte le altre fonti su TradingView.